Not available
Quote | Acasti Pharma Inc. (NASDAQ:ACST)
Last: | $3.04 |
---|---|
Change Percent: | 0.0% |
Open: | $3.03 |
Close: | $3.04 |
High: | $3.15 |
Low: | $3.0101 |
Volume: | 8,569 |
Last Trade Date Time: | 07/16/2024 03:00:00 am |
News | Acasti Pharma Inc. (NASDAQ:ACST)
PRINCETON, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemor...
2024-06-21 09:17:09 ET More on Acasti Pharma Seeking Alpha’s Quant Rating on Acasti Pharma Historical earnings data for Acasti Pharma Financial information for Acasti Pharma Read the full article on Seeking Alpha For further details see: Ac...
Message Board Posts | Acasti Pharma Inc. (NASDAQ:ACST)
Subject | By | Source | When |
---|---|---|---|
Looks pretty positive | georgie18 | investorshub | 06/21/2023 11:24:18 AM |
$ACST bulls and bears | Eurotradr | investorshub | 06/18/2023 3:34:31 PM |
short squeeze article | Eurotradr | investorshub | 06/18/2023 12:45:36 PM |
$ACST Good news recently, we should start to see this one move | georgie18 | investorshub | 06/14/2023 5:48:39 PM |
$ACST should we be shorting? | xLeGenDx | investorshub | 06/13/2023 3:22:26 AM |
News, Short Squeeze, Breakout and More Instantly...
PRINCETON, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemor...
Patient Enrollment in Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 On-Track for Potential NDA Submission in 1H Calendar 2025 Projected Cash Runway into Second Calendar Quarter 2026 PRINCETON, N.J., June 21, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (...